As of 2025-11-14, the EV/EBITDA ratio of Karyopharm Therapeutics Inc (KPTI) is -3.27. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KPTI's latest enterprise value is 272.84 mil USD. KPTI's TTM EBITDA according to its financial statements is -83.37 mil USD. Dividing these 2 quantities gives us the above KPTI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.9x - 14.7x | 13.1x |
| Forward P/E multiples | 20.9x - 22.1x | 21.9x |
| Fair Price | (196.04) - (144.27) | (167.41) |
| Upside | -3664.3% - -2723.0% | -3143.7% |
| Date | EV/EBITDA |
| 2025-11-14 | -3.28 |
| 2025-11-13 | -3.27 |
| 2025-11-12 | -3.28 |
| 2025-11-11 | -3.27 |
| 2025-11-10 | -3.27 |
| 2025-11-07 | -3.23 |
| 2025-11-06 | -3.24 |
| 2025-11-05 | -3.26 |
| 2025-11-04 | -3.29 |
| 2025-11-03 | -3.34 |
| 2025-10-31 | -3.31 |
| 2025-10-30 | -3.33 |
| 2025-10-29 | -3.34 |
| 2025-10-28 | -3.37 |
| 2025-10-27 | -3.38 |
| 2025-10-24 | -3.37 |
| 2025-10-23 | -3.36 |
| 2025-10-22 | -3.35 |
| 2025-10-21 | -3.38 |
| 2025-10-20 | -3.39 |
| 2025-10-17 | -3.32 |
| 2025-10-16 | -3.34 |
| 2025-10-15 | -3.33 |
| 2025-10-14 | -3.31 |
| 2025-10-13 | -3.29 |
| 2025-10-10 | -3.27 |
| 2025-10-09 | -3.31 |
| 2025-10-08 | -3.32 |
| 2025-10-07 | -3.31 |
| 2025-10-06 | -3.35 |
| 2025-10-03 | -3.38 |
| 2025-10-02 | -3.37 |
| 2025-10-01 | -3.36 |
| 2025-09-30 | -3.40 |
| 2025-09-29 | -3.37 |
| 2025-09-26 | -3.40 |
| 2025-09-25 | -3.41 |
| 2025-09-24 | -3.44 |
| 2025-09-23 | -3.51 |
| 2025-09-22 | -3.31 |
| 2025-09-19 | -3.26 |
| 2025-09-18 | -3.30 |
| 2025-09-17 | -3.34 |
| 2025-09-16 | -3.36 |
| 2025-09-15 | -3.36 |
| 2025-09-12 | -3.39 |
| 2025-09-11 | -3.41 |
| 2025-09-10 | -3.36 |
| 2025-09-09 | -3.37 |
| 2025-09-08 | -3.36 |